文献速递肾移植

肾移植后代谢综合征状态变化的临床意义:一项全国性前瞻性队列研究

Clinical implications of changes in metabolic syndrome status after kidney transplantation: a nationwide prospective cohort study.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该研究分析2014至2020年登记于全国性前瞻性队列的4187例肾移植受者,按移植前后代谢综合征(MetS)状态分为四组。移植前无MetS者中19.6%(419/2135)移植后新发MetS,移植前有MetS者中38.7%(794/2052)移植后MetS消失。新发MetS组移植肾丢失风险升高(aHR 2.35;95%CI 1.17-4.98),持续MetS组心血管事件和死亡复合风险升高(aHR 2.46;95%CI 1.12-5.63)。

要点

  • 移植前无MetS者中19.6%移植后新发MetS,移植前有MetS者中38.7%移植后MetS消失。
  • 新发MetS组移植肾丢失风险较无MetS组升高(aHR 2.35;95%CI 1.17-4.98)。
  • 持续MetS组心血管事件和死亡复合风险较无MetS组升高(aHR 2.46;95%CI 1.12-5.63)。

核心结论

  • 肾移植显著改变代谢状态。
  • 移植后新发MetS与移植肾丢失风险升高相关。
  • 移植前后持续MetS与心血管事件和患者生存风险升高相关。

研究设计与样本

  • 全国性前瞻性队列研究,分析2014至2020年登记的4187例肾移植受者。
  • MetS定义为存在三个或以上代谢综合征组分。
  • 按移植前和移植后MetS状态分为无MetS组、新发MetS组、MetS消失组和持续MetS组。

主要发现

  • 移植前无MetS者中19.6%(419/2135)移植后新发MetS。
  • 移植前有MetS者中38.7%(794/2052)移植后MetS消失。
  • 四组中,新发MetS组移植肾存活率最差,持续MetS组无复合事件生存率较差。
  • 与无MetS组相比,新发MetS组移植肾丢失风险升高(aHR 2.35;95%CI 1.17-4.98),且移植肾丢失风险随功能异常MetS组分数量增加而升高。
  • 持续MetS组心血管事件和死亡风险升高(aHR 2.46;95%CI 1.12-5.63),但功能异常MetS组分数量的变化与之心血管事件和死亡风险无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic syndrome (MetS) is prevalent in patients with end-stage kidney disease, and kidney transplantation is expected to modify the metabolic status. However, whether changes in metabolic status at the time of transplantation affect recipient outcomes remains unclear. METHODS: We analyzed 4187 recipients registered in a nationwide prospective cohort from 2014 to 2020. MetS was defined as the presence of three or more components of the metabolic syndrome. Patients were classified based on the pre- and post-transplant MetS status: MetS-free, MetS-developed, MetS-recovered and MetS-persistent. Study outcomes were occurrence of death-censored graft loss and a composite of cardiovascular events and death. RESULTS: Among recipients without pre-transplant MetS, 19.6% (419/2135) developed post-transplant MetS, and MetS disappeared in 38.7% (794/2052) of the recipients with pre-transplant MetS. Among the four groups, the MetS-developed group showed the worst graft survival rate, and the MetS-persistent group had a poorer composite event-free survival rate. Compared with the MetS-free group, the MetS-developed group was associated with an increased risk of graft loss [adjusted hazard ratio (aHR) 2.35; 95% confidence interval (CI) 1.17-4.98] and the risk of graft loss increased with increasing numbers of dysfunctional MetS components. MetS-persistent was associated with increased risks of cardiovascular events and death (aHR 2.46; 95% CI 1.12-5.63), but changes in the number of dysfunctional MetS components was not. CONCLUSION: Kidney transplantation significantly alters the metabolic status. Newly developed MetS after transplantation was associated with an increased risk of graft loss, whereas persistent MetS exposure before and after transplantation was associated with increased risks cardiovascular events and patient survival.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lee YH, Song SH, Song SH, et al. Clinical implications of changes in metabolic syndrome status after kidney transplantation: a nationwide prospective cohort study. Nephrol Dial Transplant. 2023. PMID: 37243323. doi:10.1093/ndt/gfad115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。